News 07.07.2026 Microcaps AG, the Swiss precision microencapsulation company, announced today a strategic collaboration and equity investment from Givaudan, the global leader in Fragrance & Beauty. This collaboration strengthens Microcaps‘ encapsulation technology and its position as an innovator in the fragrance and beauty industry. Encapsulation technology plays a pivotal role in enhancing fragrance...
News 06.07.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today provided an...
News 02.07.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and VILLEJUIF, France, July 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners”), and Orano Med, a...
News 01.07.2026 PARIS, FRANCE AND SCHLIEREN/ZURICH, SWITZERLAND, 01 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) and Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and outstanding shares of Memo Therapeutics AG. The anticipated acquisition is focused...
News 29.06.2026 Neurimmune announced today that safety and efficacy data of the long-term follow up of the NI006-101 trial of cliramitug (formerly NI006, ALXN2220) for the treatment of amyloid transthyretin cardiomyopathy (ATTR-CM) have been published in Nature Medicine by Peter C. Kahr et al.1 ATTR-CM is a systemic and potentially life-threatening disease caused by...